AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04861727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical intervention
Description: The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
Study NCT06577779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
Study NCT06577779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
Study NCT04648761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL algorithm
Description: The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
Study NCT05218967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
Study NCT05049018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy Program
Description: This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities.
Study NCT05049018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Program
Description: This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities.
Study NCT05049018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)
Description: ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
Study NCT05177822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
Study NCT05177822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
Study NCT03811886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study.
Study NCT06439563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 10 mg
Description: JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
Study NCT06439563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanston Capsule 15 mg
Description: Lanston Capsule 15 mg orally once a day for up to 24 weeks
Study NCT06439563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JP-1366 10 mg placebo
Description: JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
Study NCT06439563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanston Capsule 15 mg placebo
Description: Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
Study NCT06354712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-Cysteine with Institutional standard care
Description: A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
Study NCT06354712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Institutional standard care
Description: Benzydamine Mouthwash
Study NCT04645160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion
Study NCT05664009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Redsenol-1 Plus
Description: Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
Study NCT05664009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
Study NCT04822025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 (High-Dose)
Description: Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Study NCT04822025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Mid-Dose)
Description: Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Study NCT05858047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily (QD)
Study NCT05858047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)
Study NCT05041478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
Study NCT05041478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Snare Endoscopic Mucosal Resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
Study NCT04715711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm coolng
Description: forearm immersion will be performed for active cooling assessment
Study NCT04715711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wet-towel cooling
Description: Wet towels will be wrapped around the participant's arms for active cooling
Study NCT04715711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mist-fan
Description: a mist-fan will be placed in front of the participant for active cooling
Study NCT04715711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: passive cooling
Description: participants will sit in a chair and passively cool (no active intervention)
Study NCT05559164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 40mg Tablet
Description: LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
Study NCT04864236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel isolation device to contain aerosol
Description: The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso.
Study NCT03017716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
Study NCT05063162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab.
Study NCT05063162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo.
Study NCT04908800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-A218
Description: KRP-A218 tablet
Study NCT04908800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04908800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 10 mg/mL oral solution
Study NCT06646146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting combine with hair transplantation
Description: Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
Study NCT06646146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hair transplantation
Description: Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
Study NCT03978702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
Study NCT05785520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ST500 SINGLE-DOSE GEL
Description: ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
Study NCT05245773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated SMS program to support post-discharge transitions of care
Description: The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
Study NCT06378983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral isotretinoin
Description: Oral isotretinoin
Study NCT06378983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin combined with microneedle radiofrequency therapy
Description: Oral isotretinoin combined with microneedle radiofrequency therapy
Study NCT05765110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF drug state
Description: Experiment will be performed without dopaminergic medication
Study NCT05765110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS OFF state
Description: Turning off the stimulation during experiment
Study NCT05765110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON drug state
Description: Experiment will be performed with dopaminergic medication
Study NCT05765110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS ON state
Description: Experiment will be performed with stimulation (ON condition)
Study NCT06214026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META-Arc foot locked
Description: Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.
Study NCT06214026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META-Arc foot unlocked
Description: Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
Study NCT06646068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Philips 66 with CBL
Description: Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
Study NCT04888650 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: electronic questionnaire
Study NCT04829695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine drug combination
Description: Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Study NCT06537362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece with cheek-holder
Description: A cheek support integrated into the mouthpiece is used for the measures
Study NCT05320861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SJP-0008
Description: Single oral dose of \[14C\]SJP-0008
Study NCT05271799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered
Study NCT06453304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Intracanal medication
Study NCT06453304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix
Description: Intracanal medication
Study NCT06453304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycirrhizin
Description: Intracanal medication
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Investigator's choice; administered by intravenous infusion
Study NCT05635708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered Orally
Study NCT06181708 — intervention group
Intervention type: OTHER
Intervention: N/A - Questionnaire based study
Description: Questionnaire based study
Study NCT04709419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celliant Diabetic Medical Socks
Description: Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction.
Study NCT04709419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control (placebo) Medical Socks
Description: The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
Study NCT05987449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
Study NCT05146674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group).